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Population Pharmacokinetics and Pharmacodynamics of Extended-
Infusion Piperacillin and Tazobactam in Critically Ill Children
Kristen Nichols,a,b Eun Kyoung Chung,c* Chad A. Knoderer,a Lauren E. Buenger,b Daniel P. Healy,d Jennifer Dees,d
Ashley S. Crumby,b,c* Michael B. Kaysc
Butler University College of Pharmacy and Health Sciences, Indianapolis, Indiana, USAa; Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USAb;
Purdue University College of Pharmacy, West Lafayette and Indianapolis, Indiana, USAc; James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio,
USAd
The study objective was to evaluate the population pharmacokinetics and pharmacodynamics of extended-infusion piperacillin-
tazobactam in children hospitalized in an intensive care unit. Seventy-two serum samples were collected at steady state from 12
patients who received piperacillin-tazobactam at 100/12.5 mg/kg of body weight every 8 h infused over 4 h. Population pharma-
cokinetic analyses were performed using NONMEM, andMonte Carlo simulations were performed to estimate the piperacillin
pharmacokinetic profiles for dosing regimens of 80 to 100 mg/kg of the piperacillin component given every 6 to 8 h and infused
over 0.5, 3, or 4 h. The probability of target attainment (PTA) for a cumulative percentage of the dosing interval that the drug
concentration exceeds the MIC under steady-state pharmacokinetic conditions (TMIC) of>50%was calculated at MICs ranging
from 0.25 to 64 mg/liter. The mean standard deviation (SD) age, weight, and estimated glomerular filtration rate were 5 3
years, 17 6.2 kg, and 118 41 ml/min/1.73 m2, respectively. A one-compartment model with zero-order input and first-order
elimination best fit the pharmacokinetic data for both drugs. Weight was significantly associated with piperacillin clearance, and
weight and sex were significantly associated with tazobactam clearance. Pharmacokinetic parameters (mean SD) for piperacil-
lin and tazobactam were as follows: clearance, 0.22 0.07 and 0.19 0.07 liter/h/kg, respectively; volume of distribution, 0.43
0.16 and 0.37 0.14 liter/kg, respectively. All extended-infusion regimens achieved PTAs of>90% at MICs of<16 mg/liter.
Only the 3-h infusion regimens given every 6 h achieved PTAs of>90% at anMIC of 32 mg/liter. For susceptible bacterial patho-
gens, piperacillin-tazobactam doses of>80/10 mg/kg given every 8 h and infused over 4 h achieve adequate pharmacodynamic
exposures in critically ill children.
Piperacillin-tazobactam (TZP) is a broad-spectrum -lactam–-lactamase inhibitor antibiotic that is commonly used in
children with suspected or documented infection. For penicillin
antibiotics like piperacillin, microbiological and clinical outcomes
are associated with the cumulative percentage of the dosing inter-
val that the drug concentration exceeds the MIC for the organ-
ism(s) under steady-state pharmacokinetic conditions (TMIC);
optimal activity is seen when the TMIC is50% (1, 2). Prolonga-
tion of the infusion time is one strategy that has been utilized to
increase the TMIC and optimize the pharmacodynamics of TZP,
particularly for isolates with elevated MICs (1). Administration of
TZP every 8 h with an infusion time of 4 h has been well described
in adult patients (3–12). It has been demonstrated that 3.375 g
given every 8 h and infused over 4 h achieves pharmacodynamic
targets as effectively as 3.375 g given every 6 h, while it utilizes less
total drug per day, resulting in a cost reduction (9, 10). Addition-
ally, data support the improvement of clinical outcomes with ex-
tended-infusion dosing regimens compared to those achieved
with traditional dosing regimens (4, 5).
Extended-infusion TZP dosing (with a piperacillin component
of 100 mg/kg of body weight given every 8 h and infused over 4 h)
was demonstrated to be feasible in over 90% of children, but cur-
rently available pediatric data on the pharmacodynamics of ex-
tended-infusion TZP are limited to those from Monte Carlo sim-
ulations incorporating pharmacokinetic data derived from the
single or first dose of TZP infused over 0.5 h (13–16). Children
exhibit pharmacokinetic changes throughout development, and
the pharmacokinetics of drugs in children show significant differ-
ences from those in adults. Dose extrapolation from adults to
children has been shown to be associated with adverse outcomes
(17–19). While pharmacodynamic principles for many drugs can
change significantly from childhood to adulthood, antibiotics are
unique in that the target exposures for efficacy are based on the
interaction between the antibiotic and the infecting organism.
Pharmacodynamic predictors of efficacy (e.g., TMIC) for antibiot-
ics do not change from the adult to the child. While evaluations of
TZP pharmacokinetics in children are available, there are cur-
rently no published pharmacokinetic and pharmacodynamic data
from children receiving extended-infusion TZP to guide optimal
dosing on the basis of attainment of the target TMIC (14, 15, 20–
28). In addition, data regarding the population pharmacokinetics
of tazobactam in children are limited (27, 28).
The objective of this study was to determine the steady-state
population pharmacokinetics of piperacillin and tazobactam
Received 31 August 2015 Returned for modification 25 September 2015
Accepted 1 November 2015
Accepted manuscript posted online 9 November 2015
Citation Nichols K, Chung EK, Knoderer CA, Buenger LE, Healy DP, Dees J, Crumby
AS, Kays MB. 2016. Population pharmacokinetics and pharmacodynamics of
extended-infusion piperacillin and tazobactam in critically ill children. Antimicrob
Agents Chemother 60:522–531. doi:10.1128/AAC.02089-15.
Address correspondence to Kristen Nichols, knichols@butler.edu.
* Present address: Eun Kyoung Chung, Kyung Hee University College of Pharmacy,
Department of Pharmacy, Seoul, South Korea; Ashley S. Crumby, University of
Mississippi, University, Mississippi, USA.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
crossmark
522 aac.asm.org January 2016 Volume 60 Number 1Antimicrobial Agents and Chemotherapy
 o
n
 D
ecem
ber 31, 2015 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
when administered by extended infusion in children hospitalized
in a pediatric intensive care unit (ICU). Additionally, we evaluated
the pharmacodynamics of TZP using various dosing regimens and
infusion times over a range of MICs to determine the optimal
dosing regimens in this patient population.
MATERIALS AND METHODS
Patient population. Patients 9 months to 11 years of age who were admit-
ted to a pediatric intensive care unit were eligible for the study if they were
already receiving extended-infusion TZP as part of routine care for a
suspected or proven bacterial infection. Patients had to have received at
least one prior dose to qualify for the study, and adequate vascular access
was required to obtain serum samples without additional venipuncture.
Patients with an estimated glomerular filtration rate (eGFR) of 60 ml/
min/1.73 m2, as determined by the modified Schwartz equation (29), were
excluded, as were patients receiving any form of dialysis or renal replace-
ment therapy. The study was approved by the Institutional Review Board
at Indiana University, and written informed consent was obtained from
the parent or legal guardian of each child prior to sample collection. Writ-
ten informed assent was obtained from children who were awake, cogni-
tively appropriate, and capable of understanding the assent process.
Study design and blood sampling. Dosing regimens were prescribed
by the treating physician as part of routine care. TZP was dosed at 100
mg/kg of the piperacillin component (112.5 mg/kg of total TZP) every 8 h
infused over 4 h up to a usual adult dose of 3,000 mg of the piperacillin
component and 375 mg of the tazobactam component per dose, accord-
ing to a dosing protocol approved by the Pharmacy and Therapeutics
Committee at the institution. TZP was provided in a labeled syringe by the
hospital pharmacy for each patient from a stock dilution of 112.5 mg of
TZP per ml. Blood samples were collected at steady state from an already-
present indwelling intravenous or intra-arterial catheter which was not
utilized for TZP administration. Samples were obtained from each patient
immediately prior to the study dose and at 2, 4 (end of infusion), 5, 6, and
8 h after the start of the infusion of the study dose. At each time point, 0.5
ml/kg (maximum, 5 ml) of whole blood was collected in non-anticoagu-
lant-containing (red-top) tubes. After the blood was allowed to coagulate,
samples were centrifuged, and serum samples were stored frozen at70°C.
Serum samples were shipped on dry ice by overnight carrier to the University
of Cincinnati Academic Health Center (Cincinnati, OH) for determination of
piperacillin and tazobactam concentrations.
Piperacillin and tazobactam assay. Piperacillin and tazobactam con-
centrations were measured using a validated high-performance liquid
chromatography (HPLC) assay, as described previously (12, 30). The
standard curve for piperacillin was linear over the concentration range of
2 to 400 mg/liter (r 0.993). The within-day (n  6) and between-day
(n 8) coefficients of variation for control specimens spiked with pipera-
cillin were less than 8%. The standard curve for tazobactam was linear
over the concentration range of 2 to 100 mg/liter (r 0.991). The within-
day and between-day coefficients of variation for control specimens
spiked with tazobactam ranged from 3.9% to 10.8% over the concentra-
tion range tested. The limit of quantification for both drugs was consid-
ered to be the lowest standard concentration.
Population pharmacokinetic modeling. Serum concentration-time
data for piperacillin and tazobactam from all individual patients were
analyzed simultaneously by a population compartmental pharmacoki-
netic modeling approach using NONMEM (version VII; Globomax LLC,
Ellicott City, MD, USA), as previously described (11). Pharmacokinetic
models were built separately for piperacillin and tazobactam. For both
drugs, the first-order conditional estimation method with interaction was
used. On the basis of previous publications describing piperacillin phar-
macokinetics in children, one- and two-compartment models with zero-
order input and first-order (i.e., linear) elimination were evaluated as
potential structural pharmacokinetic models for both piperacillin and
tazobactam. The interindividual variability () of the population
pharmacokinetic parameters was assumed to follow a log-normal dis-
tribution with a mean of zero and a variance of 2 (31). Possible
correlations among the interindividual variabilities for pharmacoki-
netic parameters in the model were examined using the OMEGA
BLOCK functionality in NONMEM.
For residual errors (ε) unexplained by the model, additive (εadd), pro-
portional (εprop), and combinational models were evaluated, and residual
error was assumed to be normally distributed with a mean of zero and a
variance of 2 (31). The best structural pharmacokinetic models with
stochastic error terms for piperacillin and tazobactam were selected on the
basis of the visual inspection of observed concentration-time plots, good-
ness-of-fit plots, individual plots of observed and individual predicted
concentration-time profiles, relative standard errors, the change in the
minimum objective function value (OFV), and the Akaike information
criterion (32). Standard errors were deemed acceptable if they were50%
for fixed effects and 75% for random effects.
The final pharmacokinetic model was built by evaluating the effects of
covariates on the pharmacokinetic parameters of piperacillin and tazo-
bactam using stepwise forward inclusion (decrease in the OFV by	3.84;
P 0.05; 
2 distribution; 1 degree of freedom [df]) followed by the back-
ward elimination process (increase in the OFV by 	5.024; P 0.025; 
2
distribution; 1 df) as previously described, with modified covariates (27).
The covariates tested included age (in years); sex; height (in centimeters);
body size descriptors, including body weight (WT; in kilograms) and
body mass index (BMI), calculated as WT (in kilograms) divided by
height (in meters) squared; and eGFR, as calculated by the modified
Schwartz equation (29). Continuous covariates (e.g., age; height; body
size descriptor, including WT and BMI; and eGFR) were centered at their
median values. The full model was constructed when all significant cova-
riates were added to the model in the stepwise forward inclusion process.
Throughout the covariate model-building process, in addition to the
model OFV, shrinkage and standard errors were used to evaluate the
interindividual variability term of the PK parameters. Acceptable stan-
dard error criteria for random and fixed effects were previously described.
Covariate models with shrinkage values of30% were considered appro-
priate. The physiologic plausibility of the relationship between each cova-
riate and pharmacokinetic parameter in the model was evaluated as well.
The final model was evaluated by the use of goodness-of-fit plots and
individual plots of the observed and individual predicted concentration-
time profiles. The predictive accuracy of the final pharmacokinetic model
was examined by visual predictive checks (VPCs) (33). Visual predictive
checks were performed by simulating the serum concentration-time pro-
files for piperacillin and tazobactam using NONMEM (version VII;
Globomax LLC, Ellicott City, MD, USA). One thousand simulations were
conducted to create serum concentration-time profiles of piperacillin and
tazobactam for 12,000 virtual patients, using the data for all of the study
patients included in this study to build the population pharmacokinetic
model (n  12). Curves for the 5th, 50th, and 95th percentiles of simu-
lated drug concentrations were graphed with the observed concentra-
tions. Descriptive statistics were used to summarize patient demographics
and pharmacokinetic parameters.
Monte Carlo simulations. Pharmacodynamic exposures were mod-
eled for the following TZP dosing regimens: 80/10 mg/kg every 8 h, 80/10
mg/kg every 6 h, 100/12.5 mg/kg every 8 h, and 100/12.5 mg/kg every 6 h.
Each dosing regimen was simulated as a 0.5-h infusion, a 3-h infusion
for regimens of administration every 6 h, and a 4-h infusion for regi-
mens of administration every 8 h. Monte Carlo simulations for
piperacillin were performed on the basis of our study patient charac-
teristics using NONMEM to create steady-state serum piperacillin con-
centration-time curves for 5,040 virtual patients using the final popula-
tion pharmacokinetic model per dosing regimen. All serum
concentration-time curves were simulated in 0.1-h intervals, and the
unbound serum concentrations were calculated as the simulated se-
rum drug concentrations multiplied by the unbound fraction, which
was assumed to be 0.7 for piperacillin (34). On the basis of the simu-
lated unbound serum concentration-time profiles, the probability of
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target attainment (PTA) for piperacillin was calculated for each dosing
regimen using the pharmacodynamic targets of TMICs of 50% and
100% at specific MICs ranging from 0.25 to 64 mg/liter (15, 35).
RESULTS
Patients. Twelve patients who were receiving care in the pediatric
intensive care unit at our institution participated in the study.
Table 1 shows select demographics, TZP doses, infectious indica-
tions, and any organisms isolated for each patient. The median
age, height, weight, and eGFR were 5 years (interquartile range
[IQR], 1.75, 6.5 years), 103 cm (IQR, 81.75, 109.25 cm), 17.8 kg
(IQR, 11.4, 20 kg), and 103 ml/min/1.73 m2 (IQR, 96, 111 ml/min/
1.73 m2), respectively. The patients received a mean  standard
deviation (SD) TZP dose of 112.4 mg/kg  4.1 mg/kg and 1,903
mg 686 mg. Patients had received a median of 5 doses (range, 2
to 11 doses) before the study dose. TZP appeared to be well toler-
ated during the study.
Populationpharmacokinetic analysis. Seventy-two piperacil-
lin and tazobactam concentrations (6 samples from each of 12
patients) were included. The observed serum concentration-time
profiles of piperacillin and tazobactam were best described by a
one-compartment model with zero-order input and first-order
(linear) elimination. The model-derived pharmacokinetic param-
eters for piperacillin and tazobactam were clearance (CL) and vol-
ume of distribution (V). For piperacillin, interindividual variabil-
ity was estimated for both CL and V. The model did not support
the correlation between CL and V (change in OFV [OFV] 
0.783, correlation coefficient between CL and V [CL-V] 
38.8%). Residual error was best modeled by the proportional
form. For tazobactam, interindividual variability was estimated
only for CL. Addition of the interindividual variability term on V
did not significantly decrease the model OFV (OFV1.601).
Also, the standard error and the shrinkage value associated with
the interindividual variability term on V were large (	100% and
	30%, respectively) (36, 37). Therefore, the interindividual vari-
ability term on V was not estimated. Residual error was best mod-
eled by the combinational form.
Covariates that significantly decreased the model OFV and in-
terindividual variability in the stepwise forward process were WT
added to piperacillin CL (OFV4.517) and sex (where 1 was
used for female and 0 was used for male), followed by WT added to
tazobactam CL (OFV  4.402 for sex; OFV  7.528 for
WT). None of these covariates were removed from the models in
the backward elimination step. Therefore, the final model for pip-
eracillin (OFV  448.641) was CL (in liters per hour)  3.51 
[0.0814 · (WT  18)], and V was equal to 6.58 liters. The final
model for tazobactam (OFV  195.425) was CL (in liters per
hour) {3.43 · [1 (0.285 · sex)]} [0.0676 · (WT 18)], and
V was equal to 5.54 liters.
Table 2 summarizes the model-estimated population pharma-
cokinetic parameters and their associated interindividual variabil-
ity for piperacillin and tazobactam. Figures 1 and 2 show basic
goodness-of-fit plots for the final population pharmacokinetic
models for piperacillin and tazobactam, respectively. For pipera-
cillin, the final model appeared to slightly underpredict the ob-
served concentrations at high observed concentrations (	130 mg/
liter). For tazobactam, few data points were notably deviated from
the line of identity near the observed tazobactam concentrations
of 5, 10, and 20 mg/liter. Overall, the goodness-of-fit plots dem-
onstrated no apparent systematic bias for the final pharmacoki-
netic models for both piperacillin and tazobactam. Visual predic-
tive checks with the 90% prediction intervals using the final
population pharmacokinetic model graphed with the observed
drug concentrations are shown in Fig. 3a and b for piperacillin and
tazobactam, respectively. On the basis of the VPC plots (Fig. 3a
and b), the final models adequately predicted the observed drug
concentrations, with most of the observed data being within the
90% prediction interval. Table 3 summarizes the values for the
piperacillin and tazobactam pharmacokinetic parameters esti-
mated by the final models.
Monte Carlo simulation. Figure 4 shows the PTA for pipera-
cillin at the pharmacodynamic targets of TMICs of 50% and
100% for the TZP dosing regimens evaluated. At the pharma-
codynamic target of a TMIC of50% (Fig. 4a), all simulated dos-
ing regimens achieved a PTA of 	90% at MICs of 8 mg/liter.
Only 0.5-h infusion regimens of 80 mg/kg and 100 mg/kg every 8
h did not achieve a PTA of	90% at an MIC of 16 mg/liter. At an
MIC of 32 mg/liter, 80 to 100 mg/kg given every 6 h and infused
over 3 h achieved a PTA of 	90%.
At the pharmacodynamic target of a TMIC of 100% (Fig. 4b),
none of the regimens achieved a PTA of	90% at an MIC of16
TABLE 2 Final population pharmacokinetic model parameters of piperacillin and tazobactama
Parameter
Final piperacillin model Final tazobactam model
Estimate (% SE) % shrinkage Estimate (% SE) % shrinkage
1 (liters/h) 3.51 (6.5) NA 3.43 (5.9) NA
2 (liters) 6.58 (10.6) NA 5.54 (8.9) NA
3 0.0814 (45.1) NA 0.285 (20.9) NA
4 (liters/h) NA NA 0.0676 (38.6) NA
Interindividual variability ()
CL 17.3% (59.0) 10.3% 13.1% (52.1) 11.2%
V 25.2% (59.1) 18.0% NA NA
Residual error ()
proportional 25.3% (28.7) 10.3% 27.2% (35.2) 5.8%
additive NA NA 0.76 mg/liter (47.8) 5.8%
a The final piperacillin model was TVCL  1  [3 · (WT  18)] and TVV  2. The final tazobactam model was TVCL  [1 · (1  3 · sex)]  [4 · (WT  18)] and TVV  2,
where sex is coded 1 if female and 0 otherwise, TVCL is the typical population value of clearance (in liters per hour), WT is body weight (in kilograms), and TVV is the typical
population value of the volume of distribution (in liters). NA, not applicable.
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mg/liter, and only 100 mg/kg given every 6 h and infused over 3 h
achieved a PTA of 	90% at an MIC of 8 mg/liter.
DISCUSSION
To our knowledge, this is the first study to evaluate the pharma-
cokinetics and pharmacodynamics of extended-infusion TZP in
children hospitalized in an intensive care unit. The population
pharmacokinetic model that best described the observed serum
concentration-time data for piperacillin and tazobactam was a
one-compartment model with first-order (linear) elimination.
The same population pharmacokinetic model was recently de-
scribed for adults receiving TZP by extended infusion (11), and a
one-compartment model has best described extended-infusion
pharmacokinetic data for -lactams in adults (10, 12, 38, 39).
Previous studies have utilized one- and two-compartment models
to describe piperacillin and/or tazobactam serum concentration-
time data in pediatric patients receiving TZP by the traditional
0.5-h infusion (14, 15, 24, 27, 28, 40). However, the rate constants
for the transfer of piperacillin between the central and peripheral
compartments are rapid in young children and distribution may
be complete (or nearly complete) by the end of the 4-h infusion,
which results in a better fit with a one-compartment model (14).
Piperacillin CL was significantly associated with weight, and tazo-
bactam CL was significantly associated with weight and sex (Table
2). Female patients exhibited significantly slower tazobactam CL
than male patients, a finding that has not been previously re-
ported. The glomerular filtration rate (GFR), estimated using the
modified Schwartz equation (29), was not associated with pipera-
cillin or tazobactam CL, similar to the findings of previous studies
(14, 15). Potential explanations for this finding include the rela-
tively small sample size (n 12), the exclusion of patients with an
eGFR of 60 ml/min/1.73 m2, or an inaccurate estimate of the
patient’s actual GFR.
Due to the extended infusion time, maximum serum concen-
trations (Cmaxs) for piperacillin and tazobactam were substan-
tially lower in the present study than in previous studies where
comparable doses were infused over 0.5 h (20, 22). The lower Cmax
is not likely to adversely impact clinical outcomes in children,
since -lactams exhibit time-dependent bactericidal activity and
TMIC predicts outcome. It is currently unknown whether a lower
FIG 1 Goodness-of-fit plot of the final piperacillin pharmacokinetic model.
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Cmax might result in fewer adverse events. On the other hand, the
minimum serum concentrations (Cmins) at 8 h in the present
study were similar to the concentrations at 4 h in the previous
study (20). In the present study, piperacillin CL was slower and V
was larger than those in the study by Reed and colleagues (20).
They enrolled pediatric patients with suspected or proven bacte-
rial infections outside the central nervous system, but they did not
report the actual infection-related diagnoses for the patients. Dif-
ferences in CL and V may be due to physiologic changes related to
the infection, some degree of undetected renal dysfunction, or
severity of illness, since all of our patients were hospitalized in an
intensive care unit. Differences may also be related to the small
sample size and age groupings selected for this study. Piperacillin
CL was faster and V was larger in a study by Cies and colleagues,
but differences in pharmacokinetic parameters between these
studies may be due to the physiologic changes associated with
sepsis and burn injury (14). Eleven of their 13 patients were diag-
nosed with sepsis, and 3 patients were admitted with burn injury.
As patients in the ICU may be infected with less susceptible
bacteria and because the margin for error may be low, more ag-
gressive dosing for empirical therapy may be warranted to provide
adequate pharmacodynamic exposures before susceptibility data
are known. In an evaluation of 30-day mortality in children who
received TZP for the treatment of Pseudomonas aeruginosa bacte-
remia, 72% of isolates had TZP MICs of 16 mg/liter and 28%
had MICs of 32 or 64 mg/liter (41). Mortality was significantly
higher in children infected with the less susceptible strains (41). At
an MIC of 32 mg/liter, only 3-h infusions of 80 to 100 mg/kg every
6 h in our study achieved a PTA of 	90%, while none of the
regimens achieved optimal exposures at an MIC of 64 mg/liter.
Depending on the MIC distribution at an individual institution,
less aggressive empirical dosing regimens may be possible if iso-
lates with elevated MICs are infrequent. It may be appropriate to
utilize standard FDA-approved dosing regimens or decrease the
empirical extended-infusion dose after the MIC of the infecting
pathogen is known, depending on the site and severity of the in-
fection. Our data suggest equivalent exposures between tradi-
tional and extended-infusion regimens for pathogens with MICs
of 8 mg/liter. Extended-infusion regimens, including the 80-
mg/kg regimen given every 8 h, demonstrated an acceptable PTA
FIG 2 Goodness-of-fit plot of the final tazobactam pharmacokinetic model.
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(TMIC 	 50%) against isolates with slightly elevated MICs of 16
mg/liter. However, this potential for dose deescalation should be
weighed against the pharmacokinetic variability between patients
and the potential labor associated with alteration of the doses.
In addition to improved clinical outcomes, evaluations of ex-
tended-infusion TZP in adults have demonstrated a financial ben-
efit. Extended infusions allow administration of the same dose
every 8 h instead of every 6 h, thus eliminating the nursing, phar-
macy, and medication costs of 1 dose of TZP per patient on every
day of therapy. Our patients received 4-h infusions of 100/12.5
mg/kg every 8 h during this study, which is the current dosing
protocol at the Riley Hospital for Children. For stable patients
who demonstrate infection with a pathogen with an MIC of16
mg/liter, employing a dose of 80/10 mg/kg given every 8 h and
infused over 4 h would potentially result in a cost benefit by de-
creasing the medication cost via lowering of the total daily dose.
For similar dosing regimens, the present study tended to pre-
dict PTAs higher than those predicted by previous studies (13, 14).
These differences in PTAs are likely explained by the differences in
pharmacokinetic parameters described previously. Courter and
colleagues (13) performed Monte Carlo simulations incorporat-
ing the pharmacokinetic data reported by Reed and colleagues
(20). Their simulations predicted lower PTAs across a range of
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doses, most notably, a lack of optimal exposures with 0.5-h infu-
sion regimens (13). Similarly, Cies and colleagues found PTAs for
the lowest 0.5-h infusion dose in critically ill children that were
slightly lower than those that we found in our study (14). A 4-h
infusion of 100 mg/kg every 8 h was not simulated in their study,
but it is likely that it would have achieved optimal pharmacody-
namics at 16 mg/liter, similar to our findings (14). Cies and col-
leagues reported PTAs similar to those found in our study for
various regimens in patients with febrile neutropenia (15). The
values of the pharmacokinetic parameters were similar between
the 2 studies, a finding which likely explains the comparable PTAs.
When this information is applied to clinical practice, it is impor-
tant to note that only serum concentrations were measured in
these studies, and the pharmacokinetics of TZP in tissues and at
the site of the infection are unknown. While this information may
be used to predict doses that achieve PTAs of 90% for blood-
stream infections, it is possible that target attainment is underpre-
dicted for urinary tract infections and overpredicted for more
deep-seated infections. Optimal dosing for pneumonia, abscesses,
and intra-abdominal infections may be higher than that for iso-
lated bloodstream infections caused by organisms with the same
MIC. Additionally, though our pharmacokinetic data should not
be extrapolated to nonrepresentative populations, certain infec-
tions or patient populations may require a TMIC of 	50% for
optimal bactericidal activity (15). As a result, it may be prudent to
target a higher TMIC, strengthening the argument for empirical or
directed 4-h infusion regimens in certain patient populations even
when traditionally infused doses are likely to achieve a target of a
TMIC of 50%.
Dosing simulations were performed on the basis of the phar-
macokinetics and the target pharmacodynamic parameter for
the piperacillin component only, but tazobactam pharmacokinet-
ics and pharmacodynamics should not be ignored. Adequate
amounts of the -lactamase inhibitor are required to preserve the
activity of the -lactam agent against organisms producing inhib-
itor-susceptible -lactamases (42–44). The optimal pharmacody-
namic target for tazobactam against multiple-lactamases has not
been well characterized, especially in pediatric patients, so the dos-
ing recommendations in our study are based on the findings for
the piperacillin component only. Additional studies are needed to
determine the target tazobactam pharmacodynamic parameter
for maximum inhibition for multiple common -lactamases.
There are some limitations that should be considered when
evaluating the results of this study. The number of patients eval-
uated is relatively small (n  12), and six samples were collected
from each patient. Seventy-two samples may not be sufficient to
provide robust estimates of pharmacokinetic parameters in a pop-
ulation of pediatric patients hospitalized in an ICU. However,
previous studies incorporated only 31 and 48 piperacillin concen-
trations into development of the population pharmacokinetic
models (14, 15). Therefore, the number of piperacillin and tazo-
bactam concentrations was greater in this study. The presence of
concomitant medications such as vasopressors, which could im-
pact the disposition of TZP, was not evaluated. The study results
may not be applicable to younger infants or older children, since
the children completing this study were 1 to 9 years of age. Under-
lying conditions were limited in our population and may not ad-
equately predict the range of possible piperacillin exposures for
patients with other underlying conditions. Monte Carlo simula-
tions for the 0.5-h and extended-infusion dosing regimens were
performed using the piperacillin pharmacokinetic parameters es-
timated using a one-compartment model. Piperacillin exhibits bi-
or triexponential pharmacokinetics when infused over 0.5 h or
less. The use of a one-compartment model to simulate dosing
regimens infused over 0.5 h may not accurately estimate the serum
concentration-time profiles for piperacillin, which may affect the
PTA data. Therefore, clinicians should exercise caution when in-
terpreting the PTA data for 0.5-h infusion regimens.
In conclusion, the pharmacokinetics of piperacillin and tazo-
bactam administered as an extended infusion to children in an
ICU differed slightly from those in previous studies infusing TZP
over 0.5 h. These differences may be due to the patient population
studied and their underlying conditions. For bacterial pathogens
with MICs of8 mg/liter, extended-infusion dosing regimens do
not substantially improve PTA, and standard dosing regimens are
likely sufficient. However, 100/12.5 mg/kg of TZP administered as
an extended infusion every 6 to 8 h may be considered for empir-
ical or directed therapy in critically ill pediatric patients with in-
fections caused by less susceptible pathogens or if the desirable
TMIC is greater than 50%. The optimal empirical regimens will be
impacted by the typical pathogens and MIC distributions encoun-
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interval that the drug concentration exceeds the MIC for the organism(s)
under steady-state pharmacokinetic conditions; q8h, every 8 h; q6h, every 6 h.
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tered at a given institution. Prospective studies comparing out-
comes in children receiving traditional and extended-infusion
dosing regimens are needed.
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